WeLeader Biomedical Co

WeLeader Biomedical Co Tangible Book Value per Share

The Tangible Book Value per Share of WeLeader Biomedical Co (7713.TWO) as of Oct 21, 2026 is 27.71 TWD. In the previous year, Tangible Book Value per Share was 19.89 TWD — a change of 39.33% (higher).

Tangible Book Value per Share

27.71TWD

YoY

39.33%

Last updated:

Tangible Book Value per Share of WeLeader Biomedical Co is 2025 27.71 TWD. Tangible Book Value per Share of WeLeader Biomedical Co was 2024 19.89 TWD. It decreases by 39.33% higher compared to the previous year.

The WeLeader Biomedical Co Tangible Book Value per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Tangible Book Value per Share
Date
Tangible Book Value per Share
Jan 1, 2020
5.79 TWD
Jan 1, 2021
7.72 TWD
Jan 1, 2022
14.08 TWD
Jan 1, 2023
18.51 TWD
Jan 1, 2024
19.89 TWD
Jan 1, 2025
27.71 TWD
The WeLeader Biomedical Co Tangible Book Value per Share history
YEARTangible Book Value per ShareYoY
27.71TWD+39.33%
19.89TWD+7.42%
18.51TWD+31.43%
14.08TWD+82.35%
7.72TWD+33.32%
5.79TWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

WeLeader Biomedical Co Stock analysis

What does WeLeader Biomedical Co do? WeLeader Biomedical Co Ltd generates revenue through the agency and trading of in vitro diagnostic instruments and reagent-related products, primarily serving domestic markets. The company provides distribution, after-sales, and maintenance services for laboratory reagents, consumables, instruments, and equipment, alongside construction planning for medical testing laboratories. Additional services include equipment procurement, operational coaching, human resources training, and digital medical examination platforms. Domestic clients purchase these integrated solutions for healthcare facilities and laboratories. The firm's product portfolio focuses on medical testing-related services, including operational coaching and digital platform solutions, which are sold to healthcare institutions requiring comprehensive laboratory support. Distribution of in vitro diagnostic instruments and reagents forms a core revenue stream, supported by ancillary services like equipment procurement and site construction planning. These offerings target domestic healthcare providers seeking efficient laboratory management solutions. WeLeader Biomedical Co Ltd's business model combines product sales with service delivery, emphasizing domestic market penetration. The company's revenue is derived from both the sale of diagnostic instruments and reagents and the provision of specialized services such as operational coaching and digital platform access. Healthcare institutions and laboratories are the primary buyers of these integrated offerings, leveraging the company's expertise in laboratory construction and equipment maintenance. WeLeader Biomedical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about WeLeader Biomedical Co stock

Tangible Book Value per Share of WeLeader Biomedical Co is 27.71 TWD in 2025.

Tangible Book Value per Share of WeLeader Biomedical Co changed from 19.89 TWD to 27.71 TWD, representing a 39.33% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Tangible Book Value per Share WeLeader Biomedical Co since 2006 – with annual values, charts, and detailed analysis.

Tangible book value per share excludes intangible assets and goodwill, providing a more conservative measure of per-share net asset value.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — WeLeader Biomedical Co

All Key Metrics — WeLeader Biomedical Co